CV Therapeutics (CVTX)

Add a New Bulls Reason Company: CV Therapeutics (CVTX) Current price: Headline: (100 character max) Analysis: Cancel 100% agree 2 votes   Ranexa receives front line approval and updated labelling Top Contributor: Dean Morel | Created when NASDAQ:CVTX was $9.79 | Edit | History The loss is narrowing and Ranexa revenues continue to show strong growth. Simplistically, if Ranexa sales grow 15% sequentially, they should hit profitability around Q3 2009. They achieved 19% this quarter and over the last eight quarters have averaged 18% sequential growth in Ranexa sales. With the label expansion and European sales which received approval in August 15% sequential growth should be attainable. But wait, there is more...CVTX are not a one trick pony. Management have been making great moves all year and have earnt my respect. (100 character max) Cancel

Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.